Teva Pharmaceutical Industries
TEVA | NYSE
$42.57
-$1.93 (-4.34%)
At close: Nov 16, 2026, 4:00 PM ET
$42.65
+$0.08 (+0.19%)
After-hours:
Nov 16, 2026, 7:50 PM ET
Teva Pharmaceutical Industries Company Profile
Company profile explainedCompany Profile
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
Key Executives
| Name | Position |
|---|---|
| Richard Francis | President, Chief Executive Officer & Director |
| Brian Savage | Interim Chief Legal Officer |
| Eliyahu Sharon Kalif | Executive Vice President & Chief Financial Officer |
| Amir Weiss | Senior Vice President & Chief Accounting Officer |
| Christine Fox | Executive VP of US Commercial & Head of Innovative Franchise |
| Christopher J. Stevo | Senior Vice President of Investor Relations & Competitive Intelligence |
| Eric A. Hughes | Executive Vice President of Global R&D and Chief Medical Officer |
| Evan Lippman | Executive Vice President of Business Development |
| Kathleen Veit | Senior Vice President, Global Compliance & Ethics Officer |
| Matthew Shields | Executive Vice President of Global Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 08, 2026 | 3 | Filing |
| Sep 22, 2026 | 4 | Filing |
| Sep 22, 2026 | 4 | Filing |
| Sep 21, 2026 | 144 | Filing |
| Sep 18, 2026 | 144 | Filing |
| Sep 16, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 8-A12B/A | [Amend] Filing |
| Sep 14, 2026 | 25-NSE | Filing |
Teva Pharmaceutical Industries
| Country | Israel |
| IPO Date | Feb 16, 1982 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 32,008 |
| CEO | Richard D. Francis |
Contact Details
124 Dvora Hanevi’a Street Tel Aviv,
TA 6944020 Israel
Stock Details
| Ticker Symbol | TEVA |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000818686 |
| CUSIP Number | |
| ISIN Number | IL0006290147 |
| SIC Code | 2834 |
Recent News
- 13 hours ago / benzinga.comFDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder
- 5 days ago / marketbeat.comTeva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030
- 5 days ago / globenewswire.comTeva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
- 11 days ago / fool.comTeva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?
- 13 days ago / zacks.comTeva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
- 13 days ago / marketbeat.comWhat Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call
- 13 days ago / seekingalpha.comTeva Pharmaceutical Industries Limited (TEVA) Q3 2026 Earnings Call Transcript
- 14 days ago / zacks.comCompared to Estimates, Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Key Metrics
- 14 days ago / reuters.comTeva Pharm to grow more in 2027 despite US' IRA impact on Austedo
- 14 days ago / reuters.comTeva Pharmaceutical Q3 profit gain beats estimates
Add to Watchlist
Select watchlists to add or remove TEVA